ArticleOncotarget2015
Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 31 citations in OpenAlex.
- Review
- Nanomedicine for Benign Prostatic Hyperplasia: Pathological Axes and Translational Evidence.International journal of nanomedicine · 2026Review
- Modulating Benign Prostatic Hyperplasia Through Physical Activity-The Emerging Role of Myokines: A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
- The role of autophagy in prostate cancer and prostatic diseases: a new therapeutic strategy.Prostate cancer and prostatic diseases · 2024Review
- Article
- Inhibitory effects ofIranian journal of basic medical sciences · 2023Article
- Perturbed autophagy intervenes systemic lupus erythematosus by active ingredients of traditional Chinese medicine.Frontiers in pharmacology · 2022Review
- Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19.Advanced drug delivery reviews · 2021Review
- Review
- Rapamycin Eyedrops Increased CD4International journal of molecular sciences · 2020Article
- The Effects of Long-Term Immunosuppressive Therapies on the Structure of the Rat Prostate.International journal of environmental research and public health · 2020Article
- Measurement of autophagy flux in benign prostatic hyperplasia in vitro.Prostate international · 2020Article
- Superior cancer preventive efficacy of low versus high dose of mTOR inhibitor in a mouse model of prostate cancer.Oncotarget · 2020Article
- mTOR inhibitors for treatment of low-risk prostate cancer.Medical hypotheses · 2018Article
- Specific expression pattern of tissue cytokines analyzed through the Surface Acoustic Wave technique is associated with age-related spontaneous benign prostatic hyperplasia in rats.Biochemistry and biophysics reports · 2018Article
- Chronic treatment with novel nanoformulated micelles of rapamycin, Rapatar, protects diabetic heart against ischaemia/reperfusion injury.British journal of pharmacology · 2017Article
- Vanillic acid attenuates testosterone-induced benign prostatic hyperplasia in rats and inhibits proliferation of prostatic epithelial cells.Oncotarget · 2017Article
- Article
- Gerosuppression by pan-mTOR inhibitors.Aging · 2016Article
- Cinnamomi Cortex (Cinnamomum verum) Suppresses Testosterone-induced Benign Prostatic Hyperplasia by Regulating 5α-reductase.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Benign prostatic hyperplasia (BPH) is the most common age-related disease in men. Here we tested the efficacy of Rapatar, a micellar nanoformulation of rapamycin, in two rat models of BPH: testosterone-induced and sulpiride-induced hyperplasia in ventral lobes and lateral/dorsal lobes, respectively. We found that Rapatar prevented hypertrophic and hyperplastic abnormalities and degenerative alterations in both BPH models. Rapatar normalized weight of the lateral lobes in sulpiride-induced BPH, the most relevant animal model of human BPH. Unlike Finasteride, a standard therapy of BPH, Rapatar reduced inflammation caused by sulpiride. No obvious side effects of Rapatar were detected. Our data provide a rationale for clinical trials of Rapatar in patients suffering from BPH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.